Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment

被引：0
|
作者：
Rexer, H. [1 ,3 ]
Ohlmann, C. -H. [2 ]
Grimm, M. -O.
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesellschaft eV, Arbeitsgemeinschaft Urol Onkol, Berlin, Germany
[3] AUO Geschaftsstelle Frau Heidrun Rexer ViSdP, MeckEvidence H Rexer Seestr 11, D-17252 Schwarz, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 03期
关键词：
D O I：
10.1007/s00120-023-02056-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 339
页数：2
相关论文
共 50 条
  • [41] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    De Berardinis, E.
    Busetto, G. M.
    Antonini, G.
    Giovannone, R.
    Gentile, V.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2011, 43 (04) : 1047 - 1057
  • [42] T1G3 HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): CONSERVATIVE TREATMENT VERSUS IMMEDIATE CYSTECTOMY
    Busetto, Gian Maria
    Giovannone, Riccardo
    Antonini, Gabriele
    Gentile, Vincenzo
    De Berardinis, Ettore
    ANTICANCER RESEARCH, 2012, 32 (05) : 1868 - 1868
  • [43] Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
    Shelley, Mike D.
    Jones, Gabriel
    Cleves, Anne
    Wilt, Timothy J.
    Mason, Malcolm D.
    Kynaston, Howard G.
    BJU INTERNATIONAL, 2012, 109 (04) : 496 - 505
  • [44] HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP
    Gan, Christine
    Amery, Suzanne
    Chatterton, Kathryn
    Khan, Muhammad Shamim
    Thomas, Kay
    O' Brien, Tim
    JOURNAL OF UROLOGY, 2017, 197 (04): : E367 - E367
  • [45] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    EUROPEAN UROLOGY, 2022, 81 : S251 - S251
  • [46] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    E. De Berardinis
    G. M. Busetto
    G. Antonini
    R. Giovannone
    V. Gentile
    International Urology and Nephrology, 2011, 43 : 1047 - 1057
  • [47] MULTI-INSTITUTIONAL OUTCOMES OF PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WHO UNDERGO RADICAL CYSTECTOMY AFTER BCG AND SUBSEQUENT SALVAGE INTRAVESICAL THERAPY
    Packiam, Vignesh T.
    Labbate, Craig V.
    Boorjian, Stephen A.
    Tarrell, Robert F.
    Adamic, Brittany
    Mahmoud, Mohammad
    Tsivian, Matvey
    Avulova, Svetlana
    Cheville, John C.
    Karnes, R. Jeffrey
    Tollefson, Matthew K.
    Werntz, Ryan P.
    Steinberg, Gary D.
    Frank, Igor
    JOURNAL OF UROLOGY, 2020, 203 : E1126 - E1127
  • [48] THE OUTCOME OF PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER IN SWEDEN
    Wang, Eugen
    Larsson, Ulf
    Gardmark, Truls
    Malmstrom, Per-Uno
    JOURNAL OF UROLOGY, 2020, 203 : E1077 - E1077
  • [49] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Zieger, Karsten
    Wiuf, Carsten
    Jensen, Klaus Moller-Ernst
    Orntoft, Torben Falck
    Dyrskjot, Lars
    BMC CANCER, 2009, 9
  • [50] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    BMC Cancer, 9 (1)
12345